BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 14649882)

  • 1. Interleukin-4-Pseudomonas exotoxin chimeric fusion protein for malignant glioma therapy.
    Kawakami M; Kawakami K; Puri RK
    J Neurooncol; 2003 Oct; 65(1):15-25. PubMed ID: 14649882
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overexpressed cell surface interleukin-4 receptor molecules can be successfully targeted for antitumor cytotoxin therapy.
    Kawakami K; Kawakami M; Puri RK
    Crit Rev Immunol; 2001; 21(1-3):299-310. PubMed ID: 11642612
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-13 receptor-directed cytotoxin for malignant glioma therapy: from bench to bedside.
    Husain SR; Puri RK
    J Neurooncol; 2003 Oct; 65(1):37-48. PubMed ID: 14649884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intratumoral administration of recombinant circularly permuted interleukin-4-Pseudomonas exotoxin in patients with high-grade glioma.
    Rand RW; Kreitman RJ; Patronas N; Varricchio F; Pastan I; Puri RK
    Clin Cancer Res; 2000 Jun; 6(6):2157-65. PubMed ID: 10873064
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy.
    Shimamura T; Husain SR; Puri RK
    Neurosurg Focus; 2006 Apr; 20(4):E11. PubMed ID: 16709016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical development of a recombinant toxin containing circularly permuted interleukin 4 and truncated Pseudomonas exotoxin for therapy of malignant astrocytoma.
    Puri RK; Hoon DS; Leland P; Snoy P; Rand RW; Pastan I; Kreitman RJ
    Cancer Res; 1996 Dec; 56(24):5631-7. PubMed ID: 8971168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-4 receptors on human medulloblastoma tumours serve as a sensitive target for a circular permuted IL-4-Pseudomonas exotoxin fusion protein.
    Joshi BH; Leland P; Silber J; Kreitman RJ; Pastan I; Berger M; Puri RK
    Br J Cancer; 2002 Jan; 86(2):285-91. PubMed ID: 11870521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy.
    Kioi M; Husain SR; Croteau D; Kunwar S; Puri RK
    Technol Cancer Res Treat; 2006 Jun; 5(3):239-50. PubMed ID: 16700620
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In situ expression of interleukin-4 (IL-4) receptors in human brain tumors and cytotoxicity of a recombinant IL-4 cytotoxin in primary glioblastoma cell cultures.
    Joshi BH; Leland P; Asher A; Prayson RA; Varricchio F; Puri RK
    Cancer Res; 2001 Nov; 61(22):8058-61. PubMed ID: 11719427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy.
    Kawakami M; Kawakami K; Stepensky VA; Maki RA; Robin H; Muller W; Husain SR; Puri RK
    Clin Cancer Res; 2002 Nov; 8(11):3503-11. PubMed ID: 12429641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An improved circularly permuted interleukin 4-toxin is highly cytotoxic to human renal cell carcinoma cells. Introduction of gamma c chain in RCC cells does not improve sensitivity.
    Puri RK; Leland P; Obiri NI; Husain SR; Mule J; Pastan I; Kreitman RJ
    Cell Immunol; 1996 Jul; 171(1):80-6. PubMed ID: 8660841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interleukin 4 receptor-directed cytotoxin therapy for human head and neck squamous cell carcinoma in animal models.
    Strome SE; Kawakami K; Alejandro D; Voss S; Kasperbauer JL; Salomao D; Chen L; Maki RA; Puri RK
    Clin Cancer Res; 2002 Jan; 8(1):281-6. PubMed ID: 11801570
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical studies with targeted toxins in malignant glioma.
    Rainov NG; Söling A
    Rev Recent Clin Trials; 2006 May; 1(2):119-31. PubMed ID: 18473963
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IL-4 receptor-directed cytotoxin for therapy of AIDS-associated KS tumors.
    Puri RK
    Drug News Perspect; 2000 Sep; 13(7):395-402. PubMed ID: 12937611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence that IL-13R alpha2 chain in human glioma cells is responsible for the antitumor activity mediated by receptor-directed cytotoxin therapy.
    Kawakami K; Kioi M; Liu Q; Kawakami M; Puri RK
    J Immunother; 2005; 28(3):193-202. PubMed ID: 15838375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical studies with IL-13PE38QQR for therapy of malignant glioma.
    Joshi BH; Husain SR; Puri RK
    Drug News Perspect; 2000 Dec; 13(10):599-605. PubMed ID: 12879131
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human breast carcinoma cells express type II IL-4 receptors and are sensitive to antitumor activity of a chimeric IL-4-Pseudomonas exotoxin fusion protein in vitro and in vivo.
    Leland P; Taguchi J; Husain SR; Kreitman RJ; Pastan I; Puri RK
    Mol Med; 2000 Mar; 6(3):165-78. PubMed ID: 10965493
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interleukin-4 receptor expression on AIDS-associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin-4 and Pseudomonas exotoxin.
    Husain SR; Gill P; Kreitman RJ; Pastan I; Puri RK
    Mol Med; 1997 May; 3(5):327-38. PubMed ID: 9205948
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts.
    Beseth BD; Cameron RB; Leland P; You L; Varricchio F; Kreitman RJ; Maki RA; Jablons DM; Husain SR; Puri RK
    Ann Thorac Surg; 2004 Aug; 78(2):436-43; discussion 436-43. PubMed ID: 15276492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased antitumor activity of a circularly permuted interleukin 4-toxin in mice with interleukin 4 receptor-bearing human carcinoma.
    Kreitman RJ; Puri RK; Pastan I
    Cancer Res; 1995 Aug; 55(15):3357-63. PubMed ID: 7614471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.